

CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321XC000633 AGE/SEX : 33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 PATIENT ID : REEPF020790321

CLIENT PATIENT ID:

ABHA NO :

102,02,1 133 16413

RECEIVED : 09/03/2024 09:39:05 REPORTED :30/03/2024 15:15:37

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

IMPRESSION PROMINENT BRONCHO VASCULAR MARKINGS NOTED

ECG

ECG NORMAL SINUS RHYTHM

MEDICAL HISTORY

RELEVANT PRESENT HISTORY C/O VITILIGO ON TREATMENT SINCE 2 MONTH

RELEVANT PAST HISTORY NOT SIGNIFICANT RELEVANT PERSONAL HISTORY NOT SIGNIFICANT

MENSTRUAL HISTORY (FOR FEMALES)

LMP (FOR FEMALES)

RELEVANT FAMILY HISTORY

REGULAR

11/02/2024

DIABETES

OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.55 mts
WEIGHT IN KGS. 58.3 Kgs

BMI 24 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL

Dr.Sahil .N.Shah Consultant Radiologist

Dr.Priyank Kapadia Physician

P. V. Kapadia





Page 1 Of 23

View Details

View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05 REPORTED: 30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

NORMAL PHYSICAL ATTITUDE

HEALTHY GENERAL APPEARANCE / NUTRITIONAL

STATUS

AVERAGE BUILT / SKELETAL FRAMEWORK **NORMAL** FACIAL APPEARANCE SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

NOT ENLARGED THYROID GLAND

NORMAL TEMPERATURE PULSE 78/MIN RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

ΒP mm/Hg 118/74 MM HG

> (SITTING) **NORMAL**

PERICARDIUM APEX BEAT **NORMAL**

HEART SOUNDS S1, S2 HEARD NORMALLY

ABSENT MURMURS

RESPIRATORY SYSTEM

NORMAL SIZE AND SHAPE OF CHEST SYMMETRICAL MOVEMENTS OF CHEST BREATH SOUNDS INTENSITY **NORMAL**

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT**

Dr.Sahil .N.Shah **Consultant Radiologist**

Dr.Priyank Kapadia **Physician**

P. V. Kapadia



Page 2 Of 23



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05

DELHI ABHA NO REPORTED: 30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

PER ABDOMEN

APPEARANCE NORMAL **NOT PALPABLE** LIVER **NOT PALPABLE SPLEEN**

CENTRAL NERVOUS SYSTEM

NORMAL HIGHER FUNCTIONS CRANIAL NERVES **NORMAL NORMAL** CEREBELLAR FUNCTIONS SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES NORMAL**

MUSCULOSKELETAL SYSTEM

SPINE NORMAL **NORMAL** JOINTS

SUMMARY

NOT SIGNIFICANT RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS HBA1C:- PRE-DIABETIC, MEAN PLASMA GLUCOSE:- HIGH

LDL:- HIGH

RELEVANT NON PATHOLOGY DIAGNOSTICS CHEST X-RAY: - PROMINENT BRONCHO VASCULAR MARKINGS NOTED

Dr.Sahil .N.Shah **Consultant Radiologist**

Dr.Priyank Kapadia **Physician**

P. V. Kapadia



Page 3 Of 23







Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05

REPORTED :30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

1) HBA1C:- PRE-DIABETIC, MEAN PLASMA GLUCOSE:- HIGH REMARKS / RECOMMENDATIONS

> ADV:- REDUCE INTAKE OF SWEET, SUGAR, STARCH IN DIET, REGULAR PHYSICAL EXERCISE, REPEAT FBS, PPBS AND HBA1C AND PHYSICIAN

OPINION SOS

2) LDL:- HIGH

ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY: - DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST: - DR. SAHIL N SHAH (M.D.RADIOLOGY)

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kapadia

Dr.Priyank Kapadia **Physician**





Page 4 Of 23



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID:

RECEIVED: 09/03/2024 09:39:05 REPORTED: 30/03/2024 15:15:37

Test Report Status Results Units <u>Final</u>

ABHA NO

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

TMT OR ECHO

CLINICAL PROFILE

2D ECHO:-

- 1) NORMAL CHAMBERS AND VALVES.
- 2) GOOD LV SYSTOLIC FUNCTION. LVEF 60%. NO RWMA AT REST.
- 3) NO MR, AR, TR.
- 4) NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.
- 7) IAS/IVS INTACT.

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kapadia

Dr.Priyank Kapadia **Physician**





Page 5 Of 23



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





 CODE/NAME & ADDRESS : C000138364
 ACCESSION NO : 0321XC000633
 AGE/SEX : 33 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05

Test Report Status <u>Final</u> Results Biological Reference Interval Units

| Н | IAEMATOLOGY - CE | BC | |
|---|------------------|--------------|---------|
| MEDI WHEEL FULL BODY HEALTH CHECKUP BI | ELOW 40FEMALE | | |
| BLOOD COUNTS,EDTA WHOLE BLOOD | | | |
| HEMOGLOBIN (HB) | 13.0 | 12.0 - 15.0 | g/dL |
| METHOD: PHOTOMETRIC MEASUREMENT | 4.62 | 2.0.4.0 | il / l |
| RED BLOOD CELL (RBC) COUNT METHOD: COULTER PRINCIPLE | 4.63 | 3.8 - 4.8 | mil/μL |
| WHITE BLOOD CELL (WBC) COUNT | 7.51 | 4.0 - 10.0 | thou/µL |
| METHOD : COULTER PRINCIPLE | | | |
| PLATELET COUNT | 247 | 150 - 410 | thou/µL |
| METHOD : COULTER PRINCIPLE | | | |
| | | | |
| RBC AND PLATELET INDICES | | | |
| HEMATOCRIT (PCV) | 40.5 | 36.0 - 46.0 | % |
| METHOD : CALCULATED | 07.4 | 02.0 101.0 | fL |
| MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM | 87.4 | 83.0 - 101.0 | IL |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) | 28.0 | 27.0 - 32.0 | pg |
| METHOD: CALCULATED | | | |
| MEAN CORPUSCULAR HEMOGLOBIN | 32.0 | 31.5 - 34.5 | g/dL |
| CONCENTRATION (MCHC) METHOD : CALCULATED | | | |
| RED CELL DISTRIBUTION WIDTH (RDW) | 13.6 | 11.6 - 14.0 | % |
| METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM | 10.0 | | |
| MENTZER INDEX METHOD : CALCULATED PARAMETER | 18.9 | | |
| MEAN PLATELET VOLUME (MPV) | 8.4 | 6.8 - 10.9 | fL |
| METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM | | | |
| | | | |
| WBC DIFFERENTIAL COUNT | | | |
| NEUTROPHILS | 66 | 40 - 80 | % |
| METHOD : OPTICAL IMPEDENCE & MICROCSOPY | - | | |
| LYMPHOCYTES | 26 | 20 - 40 | % |

Page 6 Of 23





View Details

View Report

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India

Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

METHOD: OPTICAL IMPEDENCE & MICROCSOPY





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHI

ABHA NO REPORTED :30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

| | i | | |
|--|----------|----------------------|----------------|
| Test Report Status <u>Final</u> | Results | Biological Reference | Interval Units |
| | | | |
| MONOCYTES | 5 | 2.0 - 10.0 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |
| EOSINOPHILS | 3 | 1.0 - 6.0 | % |
| METHOD: OPTICAL IMPEDENCE & MICROCSOPY | | | |
| BASOPHILS | 0 | 0 - 1 | % |
| METHOD: IMPEDANCE | | | |
| ABSOLUTE NEUTROPHIL COUNT | 4.96 | 2.0 - 7.0 | thou/µL |
| METHOD: CALCULATED | | | |
| ABSOLUTE LYMPHOCYTE COUNT | 1.95 | 1.0 - 3.0 | thou/μL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE MONOCYTE COUNT | 0.38 | 0.2 - 1.0 | thou/μL |
| METHOD: CALCULATED PARAMETER | | | |
| ABSOLUTE EOSINOPHIL COUNT | 0.23 | 0.02 - 0.50 | thou/μL |
| METHOD : CALCULATED | | | |
| ABSOLUTE BASOPHIL COUNT | 0.00 Low | 0.02 - 0.10 | thou/μL |
| METHOD: CALCULATED | | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | 2.5 | | |
| | | | |

MORPHOLOGY

METHOD: CALCULATED PARAMETER

NORMOCYTIC NORMOCHROMIC **RBC**

METHOD: MICROSCOPIC EXAMINATION

NORMAL MORPHOLOGY **WBC**

METHOD: MICROSCOPIC EXAMINATION

ADEQUATE PLATELETS METHOD: MICROSCOPIC EXAMINATION

NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED. **REMARKS** METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Page 7 Of 23





View Report

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : REEPF020790321

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05

DELHI ABHA NO REPORTED :30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Page 8 Of 23





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





mm at 1 hr

REF. DOCTOR: SELF PATIENT NAME: REEPAL N PANDEY

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05

REPORTED :30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval Final** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 37 High 0 - 20

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic: < 5.7 HBA1C 5.9 High %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 122.6 High < 116.0 mg/dL

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an ondition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Earloger infection, agring. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Page 9 Of 23





View Report



Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





DRAWN

REF. DOCTOR: SELF PATIENT NAME: REEPAL N PANDEY

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : REEPF020790321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05

DELHI ABHA NO REPORTED: 30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Page 10 Of 23





View Report



Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

DELHI ABHA NO **NEW DELHI 110030** 8800465156

DRAWN RECEIVED: 09/03/2024 09:39:05 REPORTED :30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE O **ABO GROUP**

METHOD: TUBE AGGLUTINATION

NEGATIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Comments

RH NEGATIVE GROUP IS CONFIRMED BY DU TEST.

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

Page 11 Of 23









CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321XC000633 AGE/SEX : 33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID:

REEPFU2U/9U321 DRAWN

RECEIVED : 09/03/2024 09:39:05 REPORTED : 30/03/2024 15:15:37

mg/dL

Test Report Status <u>Final</u> Results Biological Reference Interval Units

ABHA NO

| | IIST | |
|--|------|--|
| | | |
| | | |

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 88 74 - 99

METHOD: HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 127 70 - 140 mg/dL

METHOD: HEXOKINASE

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL 197 Desirable: < 200 mg/dL

BorderlineHigh: 200 - 239

 $\mbox{High:} > \mbox{or} = 240$ $\mbox{method:} \mbox{enzymatic, colorimetric}$

TRIGLYCERIDES 112 Desirable: < 150 mg/dL

BorderlineHigh: 150 - 199

High: 200 - 499

Very High: > or = 500

 ${\tt METHOD}: {\tt ENZYMATIC}, {\tt COLORIMETRIC}$

HDL CHOLESTEROL 50 < 40 Low mg/dL

> or = 60 High

CHOLESTEROL LDL 125 High Adult levels: mg/dL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189

Very high: = 190

NON HDL CHOLESTEROL **147 High** Desirable: Less than 130 mg/dL

Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

VERY LOW DENSITY LIPOPROTEIN 22.4 < or = 30 mg/dL

Page 12 Of 23





View Details

View Repor

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





PATIENT NAME: REEPAL N PANDEY REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : REEPF020790321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHI ABHA NO REPORTED: 30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

| Test Report Status | <u>Final</u> | Results | Biological Reference Interval Units |
|--------------------|--------------|---------|-------------------------------------|
| | | | |
| CHOL/HDL RATIO | | 3.9 | 3.3 - 4.4 |
| LDL/HDL RATIO | | 2.5 | 0.5 - 3.0 Desirable/Low Risk |
| | | | 3.1 - 6.0 Borderline/Moderate |
| | | | Risk |
| | | | >6.0 Hiah Risk |

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

| Risk Category | | | |
|--|---|---|--|
| Extreme risk group | A.CAD with > 1 feature of high risk group | | |
| | B. CAD with > 1 feature of Very high risk g | group or recurrent ACS (within 1 year) despite LDL-C < or = | |
| | 50 mg/dl or polyvascular disease | | |
| Very High Risk | 1. Established ASCVD 2. Diabetes with 2 1 | najor risk factors or evidence of end organ damage 3. | |
| | Familial Homozygous Hypercholesterolemi | a | |
| High Risk | 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ | | |
| | | 90 mg/dl 5. Extreme of a single risk factor. 6. Coronary | |
| | Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque | | |
| Moderate Risk | 2 major ASCVD risk factors | | |
| Low Risk | 0-1 major ASCVD risk factors | | |
| Major ASCVD (Ath | erosclerotic cardiovascular disease) Risk Fa | ictors | |
| 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use | | 3. Current Cigarette smoking or tobacco use | |
| 2. Family history of p | 2. Family history of premature ASCVD 4. High blood pressure | | |
| 5. Low HDL | | | |

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

| Risk Group | Treatment Goals | Treatment Goals | | herapy |
|-------------------------------|--|--|---------------|-----------------|
| | LDL-C (mg/dl) | Non-HDL (mg/dl) | LDL-C (mg/dl) | Non-HDL (mg/dl) |
| Extreme Risk Group Category A | <50 (Optional goal < OR = 30) | <80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or> | >OR = 50 | >OR = 80 |
| Extreme Risk Group Category B | <or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or> | <or 60<="" =="" td=""><td>> 30</td><td>>60</td></or> | > 30 | >60 |
| Very High Risk | <50 | <80 | >OR= 50 | >OR= 80 |
| High Risk | <70 | <100 | >OR= 70 | >OR= 100 |
| Moderate Risk | <100 | <130 | >OR= 100 | >OR= 130 |
| Low Risk | <100 | <130 | >OR= 130* | >OR= 160 |

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

Page 13 Of 23





View Details

View Report

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : **0321XC000633** AGE/SEX : 33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST
CLIENT PATIENT ID:
RECEIVED: 09/03/2024 09:39:05

DELHÍ RECEIVED : 09/03/2024 09:39:05
NEW DELHI 110030 REPORTED : 30/03/2024 15:15:37
8800465156

| | <u> </u> | <u> </u> | |
|---|------------|------------------------------|----------|
| Test Report Status <u>Final</u> | Results | Biological Reference Interva | al Units |
| | | | |
| BILIRUBIN, TOTAL | 0.34 | Upto 1.2 | mg/dL |
| BILIRUBIN, DIRECT | 0.17 | Upto 0.2 | mg/dL |
| METHOD : DIAZO COLORIMETRIC | | | |
| BILIRUBIN, INDIRECT | 0.17 | 0.00 - 1.00 | mg/dL |
| TOTAL PROTEIN METHOD: COLORIMETRIC | 7.0 | 6.4 - 8.3 | g/dL |
| ALBUMIN | 4.9 | 3.5 - 5.2 | g/dL |
| METHOD : BROMOCRESOL GREEN | | | |
| GLOBULIN | 2.1 | 2.0 - 4.1 | g/dL |
| ALBUMIN/GLOBULIN RATIO | 2.3 High | 1.0 - 2.0 | RATIO |
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE | 14 | 0 - 32 | U/L |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE | 12 | 0 - 33 | U/L |
| ALKALINE PHOSPHATASE METHOD: COLORIMETRIC | 90 | 35 - 104 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC | 20 | 5 - 36 | U/L |
| LACTATE DEHYDROGENASE METHOD: UV ASSAY METHOD | 159 | 135 - 214 | U/L |
| | | | |
| BLOOD UREA NITROGEN (BUN), SERUM | | | |
| BLOOD UREA NITROGEN | 10 | 6 - 20 | mg/dL |
| | | | |
| CREATININE, SERUM | | | |
| CREATININE METHOD: JAFFE ALKALINE PICRATE | 0.55 Low | 0.60 - 1.10 | mg/dL |
| | | | |
| BUN/CREAT RATIO | | | |
| BUN/CREAT RATIO | 18.18 High | 5.0 - 15.0 | |

Page 14 Of 23





View Details

View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHÍ

REPORTED :30/03/2024 15:15:37 ABHA NO **NEW DELHI 110030** 8800465156

| Final Final | Results | Biological Referenc | e Interval Units |
|---|------------|---------------------|------------------|
| | | | |
| URIC ACID, SERUM | | | |
| JRIC ACID | 5.4 | 2.4 - 5.7 | mg/dL |
| TOTAL PROTEIN, SERUM | | | |
| TOTAL PROTEIN METHOD: COLORIMETRIC | 7.0 | 6.4 - 8.3 | g/dL |
| ALBUMIN, SERUM | | | |
| ALBUMIN METHOD: BROMOCRESOL GREEN | 4.9 | 3.5 - 5.2 | g/dL |
| GLOBULIN | | | |
| GLOBULIN | 2.1 | 2.0 - 4.1 | g/dL |
| ELECTROLYTES (NA/K/CL), SERUM | | | |
| SODIUM, SERUM METHOD : ISE | 140.1 | 136 - 145 | mmol/L |
| POTASSIUM, SERUM METHOD : ISE | 4.08 | 3.3 - 5.1 | mmol/L |
| CHLORIDE, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY | 107.9 High | 98 - 106 | mmol/L |

Interpretation(s)

| Sodium | Potassium | Chloride |
|--------|-----------|----------|
| | | |

Page 15 Of 23





View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





REF. DOCTOR: SELF PATIENT NAME: REEPAL N PANDEY

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX Female :33 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05

REPORTED: 30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval** Units **Final**

Decreased in: CCF. cirrhosis. Decreased in: Low potassium Decreased in: Vomiting, diarrhea. vomiting, diarrhea, excessive intake, prolonged vomiting or diarrhea, renal failure combined with salt sweating, salt-losing RTA types I and II, deprivation, over-treatment with nephropathy, adrenal insufficiency, hyperaldosteronism, Cushing's diuretics, chronic respiratory acidosis, nephrotic syndrome, water syndrome, osmotic diuresis (e.g. diabetic ketoacidosis, excessive intoxication, SIADH. Drugs: hyperglycemia), alkalosis, familial sweating, SIADH, salt-losing thiazides, diuretics, ACE inhibitors, periodic paralysis,trauma nephropathy, porphyria, expansion of chlorpropamide,carbamazepine,anti (transient). Drugs: Adrenergic agents, extracellular fluid volume, depressants (SSRI), antipsychotics. adrenalinsufficiency, diuretics. hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics. Increased in: Dehydration Increased in: Massive hemolysis, Increased in: Renal failure, nephrotic (excessivesweating, severe severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, vomiting or diarrhea).diabetes acidosis, dehydration, renal failure. overtreatment with Addison's disease, RTA type IV, mellitus, diabetesinsipidus, saline, hyperparathyroidism, diabetes hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory water intake. Drugs: steroids. paralysis. Drugs: potassium salts, licorice.oral contraceptives. potassium- sparing diuretics.NSAIDs. alkalosis.hyperadrenocorticism. beta-blockers, ACE inhibitors, high-Drugs: acetazolamide.androgens. dose trimethoprim-sulfamethoxazole hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences:Test is helpful in hyperproteinemi, if sodium analysis delayed separation of serum, assessing normal and increased anion involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium drawing, and prolonged tourniquet distinguishing hypercalcemia due to falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum mg/dL increase in blood glucose. may cause spurious. Plasma potassium chloride) from that due to malignancy levels are normal. (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic

Page 16 Of 23





PERFORMED AT:

Agilus Diagnostics Ltd. Grand Malī, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





REF. DOCTOR: SELF PATIENT NAME: REEPAL N PANDEY

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05

REPORTED: 30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval Final** Units

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Page 17 Of 23





View Report

Agilus Diagnostics Ltd. Grand Malī, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID:

DRAWN

RECEIVED: 09/03/2024 09:39:05

REPORTED :30/03/2024 15:15:37

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

ABHA NO

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR Yellow APPEARANCE Clear

CHEMICAL EXAMINATION, URINE

| PH | 7.0 | 4.7 - 7.5 |
|---------------------------------------|-------|------------|
| METHOD: REFLECTANCE SPECTROPHOTOMETRY | | |
| SDECIEIC CDAV/ITV | 1 010 | 1 002 1 02 |

1.003 - 1.035 SPECIFIC GRAVITY 1.010 METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED **PROTEIN** METHOD: REFLECTANCE SPECTROPHOTOMETRY

GLUCOSE NOT DETECTED **NEGATIVE**

METHOD: REFLECTANCE SPECTROPHOTOMETRY **NOT DETECTED** NOT DETECTED **KETONES**

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NEGATIVE BLOOD

METHOD: REFLECTANCE SPECTROPHOTOMETRY BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY

UROBILINOGEN **NORMAL NORMAL** METHOD: REFLECTANCE SPECTROPHOTOMETRY

NITRITE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY

LEUKOCYTE ESTERASE TRACE NOT DETECTED METHOD: REFLECTANCE SPECTROPHOTOMETRY

MICROSCOPIC EXAMINATION, URINE

| RED BLOOD CELLS | NOT DETECTED | NOT DETECTED | /HPF |
|---------------------------------|--------------|--------------|------|
| METHOD: MICROSCOPIC EXAMINATION | | | |
| PUS CELL (WBC'S) | 2-3 | 0-5 | /HPF |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| EPITHELIAL CELLS | 2-3 | 0-5 | /HPF |

Page 18 Of 23





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





PATIENT NAME: REEPAL N PANDEY REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : REEPF020790321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHI ABHA NO REPORTED :30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CASTS**

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED BACTERIA NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST **NOT DETECTED** NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON REMARKS

CENTRIFUGED URINARY SEDIMENT.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

| Presence of | Conditions |
|-------------------------|---|
| Proteins | Inflammation or immune illnesses |
| Pus (White Blood Cells) | Urinary tract infection, urinary tract or kidney stone, tumors or any kind |
| | of kidney impairment |
| Glucose | Diabetes or kidney disease |
| Ketones | Diabetic ketoacidosis (DKA), starvation or thirst |
| Urobilinogen | Liver disease such as hepatitis or cirrhosis |
| Blood | Renal or genital disorders/trauma |
| Bilirubin | Liver disease |
| Erythrocytes | Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary |
| | tract infection and glomerular diseases |
| Leukocytes | Urinary tract infection, glomerulonephritis, interstitial nephritis either |
| | acute or chronic, polycystic kidney disease, urolithiasis, contamination by |
| | genital secretions |
| Epithelial cells | Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or |
| | bladder catheters for prolonged periods of time |
| | |
| Granular Casts | Low intratubular pH, high urine osmolality and sodium concentration, |
| | interaction with Bence-Jones protein |
| Hyaline casts | Physical stress, fever, dehydration, acute congestive heart failure, renal |
| | diseases |

Page 19 Of 23





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Email: customercare.ahmedabad@agilus.in

Gujrat, India Tel: 079-48912999,079-48913999,079-48914999



8800465156



Female

PATIENT NAME: REEPAL N PANDEY REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN

: REEPF020790321 F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHÍ REPORTED :30/03/2024 15:15:37 ABHA NO **NEW DELHI 110030**

Biological Reference Interval Test Report Status <u>Final</u> Results Units

| Calcium oxalate | Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of | |
|-----------------------|---|--|
| | ethylene glycol or of star fruit (Averrhoa carambola) or its juice | |
| Uric acid | arthritis | |
| Bacteria | Urinary infectionwhen present in significant numbers & with pus cells. | |
| Trichomonas vaginalis | is Vaginitis, cervicitis or salpingitis | |

Page 20 Of 23





View Report

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





 CODE/NAME & ADDRESS : C000138364
 ACCESSION NO : 0321XC000633
 AGE/SEX : 33 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

<u>Final</u>

DELHI

NEW DELHI 110030

Test Report Status

8800465156

PATIENT ID : REEPF020790321

CLIENT PATIENT ID: ABHA NO : DRAWN

RECEIVED : 09/03/2024 09:39:05 REPORTED : 30/03/2024 15:15:37

____i

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

Results

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 114.50 Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD: ECLIA

T4 9.41 Non-Pregnant Women µg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD : ECLIA

TSH (ULTRASENSITIVE) 3.800 Non Pregnant Women µIU/mL

0.27 - 4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

Page 21 Of 23





View Details

View Repor

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





PATIENT NAME: REEPAL N PANDEY REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : REEPF020790321 DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 09/03/2024 09:39:05 DELHI ABHA NO REPORTED: 30/03/2024 15:15:37 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

| Sr. No. | TSH | Total T4 | FT4 | Total T3 | Possible Conditions |
|---------|------------|----------|--------|----------|--|
| 1 | High | Low | Low | Low | (1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) |
| | | | | | Post Thyroidectomy (4) Post Radio-Iodine treatment |
| 2 | High | Normal | Normal | Normal | (1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid |
| | | | | | hormone replacement therapy (3) In cases of Autoimmune/Hashimoto |
| | | | | | thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical |
| | | | | | inflammation, drugs like amphetamines, Iodine containing drug and |
| | | | | | dopamine antagonist e.g. domperidone and other physiological reasons. |
| 3 | Normal/Low | Low | Low | Low | (1) Secondary and Tertiary Hypothyroidism |
| 4 | Low | High | High | High | (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre |
| | | | | | (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid |
| | | | | | hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 |
| | | | | | replacement therapy (7) First trimester of Pregnancy |
| 5 | Low | Normal | Normal | Normal | (1) Subclinical Hyperthyroidism |
| 6 | High | High | High | High | (1) TSH secreting pituitary adenoma (2) TRH secreting tumor |
| 7 | Low | Low | Low | Low | (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent |
| | | | | | treatment for Hyperthyroidism |
| 8 | Normal/Low | Normal | Normal | High | (1) T3 thyrotoxicosis (2) Non-Thyroidal illness |
| 9 | Low | High | High | Normal | (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies |

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

Page 22 Of 23





View Details

View Report





REF. DOCTOR: SELF PATIENT NAME: REEPAL N PANDEY

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC000633 AGE/SEX :33 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

: REEPF020790321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 09/03/2024 09:39:05 REPORTED :30/03/2024 15:15:37

Test Report Status Results Biological Reference Interval Units **Final**

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 23 Of 23







Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India

